SHANGHAI, China, Dec. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech, China’s
leading provider of pharmaceutical R&D outsourcing services announced today
that it has been named 173rd on the Deloitte Technology Fast 500 Asia Pacific
2006 ranking. This is the third consecutive year the pharmaceutical service
company has received the prestigious award, placing it in an elite group of
only 58 companies.
(Logo: http://www.prnasia.com/sa/200611271812.jpg )
The Deloitte Touche Tohmatsu (Deloitte) Technology Fast 500 Asia Pacific
award is Asia’s most objective industry-ranking standard, focusing
specifically on the technology sector. The award was first introduced in
2001 to recognize the most exceptional of Asia’s 500 fastest-growing
technology companies from industries including all areas of technology,
ranging form internet based companies to biotechnology. The 2006 list, like
years prior, is a mixture of both public and private companies.
This year’s 173rd ranking represents a 244% 3-year annual growth rate
for the pharmaceutical service company. WuXi PharmaTech is among only 58
companies to be recognized for a third consecutive year.
“We are honored to have our success once again recognized,” commented
Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “It is a great
encouragement and satisfaction to be listed alongside prominent companies
such as Infosys of India and others who have been selected for a third
consecutive year. This designation reflects highly on WuXi PharmaTech’s
commitment to quality of service, high operating standards, and
transparency,” continued Dr. Li.
About WuXi PharmaTech
Founded in 2001, Shanghai-based WuXi PharmaTech is China’s leading drug
R&D service company. As a research-driven and customer-focused company, WuXi
PharmaTech offers global pharmaceutical and biopharmaceutical companies a
diverse, value-added, and fully integrated portfolio of outsourcing services
ranging from discovery chemistry, service biology to bioanalytical chemistry,
from process chemistry to large scale GMP manufacturing. WuXi PharmaTech
assists its global partners in shorting the cycle and lowering the cost of
drug discovery and development by providing cost-effective and efficient
outsourcing solutions that save our clients both time and money. Currently,
our client list consists of 19 of the top 20 pharmaceutical, and 8 of the top
10 biopharmaceutical companies. For more information please visit
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss
Verein, its member firms, and their respective subsidiaries and affiliates.
Deloitte Touche Tohmatsu is an organization of member firms around the world
devoted to excellence in providing professional services and advice, focused
on client service through a global strategy executed locally in nearly 150
countries. With access to the deep intellectual capital of 135,000 people
worldwide, Deloitte delivers services in four professional areas-audit, tax,
consulting, and financial advisory services-and serves more than one-half of
the world’s largest companies, as well as large national enterprises, public
institutions, locally important clients, and successful, fast-growing global
growth companies. For more information please visit http://www.deloitte.com .